Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2026-03-12 DOI:10.1080/1120009X.2026.2635797

Demet Isik Bayraktar, Recep Turkel, Guzin Demirag

{"title":"Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.","authors":"Demet Isik Bayraktar, Recep Turkel, Guzin Demirag","doi":"10.1080/1120009X.2026.2635797","DOIUrl":null,"url":null,"abstract":"Anthracyclines are essential agents in the treatment of breast cancer. This study investigated the effect of anthracyclines on arteriosclerosis. The study group consisted of 60 patients not receiving anticoagulants and was divided into two groups: a treatment group (n = 30) receiving dexrazoxane and a control group (n = 30) not receiving dexrazoxane. Basal oscillometric arterial and echocardiographic cardiac parameters were recorded prior to and one month following the completion of chemotherapy protocols. In the dexrazoxane group, only left ventricular end-diastolic pressure increased in pre- and post-treatment measurements (p = 0.008). In the control group, a decrease in ejection fraction (p = 0.001) and an increase in left ventricular end-diastolic and left ventricular end-systolic pressure and left atrial anteroposterior diameter (p < 0.001) were observed. The PWV value was significantly increased in the control group (p < 0.001). In patients who have received anthracyclines, dexrazoxane was protective against arteriosclerosis as demonstrated by statistically significant changes in aortic stiffness and PWV values.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2026.2635797","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Anthracyclines are essential agents in the treatment of breast cancer. This study investigated the effect of anthracyclines on arteriosclerosis. The study group consisted of 60 patients not receiving anticoagulants and was divided into two groups: a treatment group (n = 30) receiving dexrazoxane and a control group (n = 30) not receiving dexrazoxane. Basal oscillometric arterial and echocardiographic cardiac parameters were recorded prior to and one month following the completion of chemotherapy protocols. In the dexrazoxane group, only left ventricular end-diastolic pressure increased in pre- and post-treatment measurements (p = 0.008). In the control group, a decrease in ejection fraction (p = 0.001) and an increase in left ventricular end-diastolic and left ventricular end-systolic pressure and left atrial anteroposterior diameter (p < 0.001) were observed. The PWV value was significantly increased in the control group (p < 0.001). In patients who have received anthracyclines, dexrazoxane was protective against arteriosclerosis as demonstrated by statistically significant changes in aortic stiffness and PWV values.

查看原文本刊更多论文

蒽环类药物对乳腺癌患者动脉硬化的影响及右唑嗪的保护作用。

蒽环类药物是治疗乳腺癌的重要药物。本研究探讨了蒽环类药物对动脉硬化的影响。研究组由60例未使用抗凝药物的患者组成，分为两组：治疗组（n = 30）接受右唑嗪治疗，对照组（n = 30）不接受右唑嗪治疗。在化疗方案完成前和完成后一个月记录基础动脉振荡和超声心动图心脏参数。在右唑嗪组，只有左心室舒张末期压在治疗前和治疗后升高（p = 0.008）。在对照组中，射血分数降低（p = 0.001），左室舒张末压和左室收缩末压及左房前后径升高（p = 0.001）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.